Novel naphthyloxy derivatives - Potent histamine H3 receptor ligands. Synthesis and pharmacological evaluation.

作者: Dorota Łażewska , Maria Kaleta , Stefanie Hagenow , Szczepan Mogilski , Gniewomir Latacz

DOI: 10.1016/J.BMC.2018.04.023

关键词: ChemistryIn vitroHistamine H3 receptorReceptorAnticonvulsantCYP3A4In vivoED50AntagonistPharmacology

摘要: Abstract A series of 1- and 2-naphthyloxy derivatives were synthesized evaluated for histamine H3 receptor affinity. Most compounds showed high affinities with Ki values below 100 nM. The most potent ligand, 1-(5-(naphthalen-1-yloxy)pentyl)azepane (11) displayed affinity the a value 21.9 nM. antagonist behaviour 11 was confirmed both in vitro cAMP assay (IC50 = 312 nM) vivo rat dipsogenia model (ED50 = 3.68 nM). Moreover, compound positive effects on scopolamine induced-memory deficits mice (at doses 10 15 mg/kg) an analgesic effect formalin test ED50 = 30.6 mg/kg (early phase) ED50 = 20.8 mg/kg (late phase). Another interesting compound, 1-(5-(Naphthalen-1-yloxy)pentyl)piperidine (13; H3R Ki = 53.9 nM), accepted Anticonvulsant Screening Program at National Institute Neurological Disorders Stroke/National Health (Rockville, USA). screening performed maximal electroshock seizure (MES), subcutaneous pentylenetetrazole (scPTZ) 6-Hz psychomotor animal models epilepsy. Neurologic deficit by rotarod test. Compound 13 inhibited convulsions induced MES ED50 19.2 mg/kg (mice, i.p.), 17.8 (rats, 78.1 p.o.). protection against seizures (32 mA) (i.p.) 33.1 mg/kg (44 mA) 57.2 mg/kg. Furthermore, weak influence viability tested cell lines (normal HEK293, neuroblastoma IMR-32, hepatoma HEPG2), inhibition CYP3A4 activity, no mutagenicity. Thus, these may be used as leads further search ligands promising activity.

参考文章(52)
Philip J Wiffen, Sheena Derry, R Andrew Moore, Dominic Aldington, Peter Cole, Andrew SC Rice, Michael PT Lunn, Katri Hamunen, Maija Haanpaa, Eija A Kalso, Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews. ,vol. 2013, ,(2013) , 10.1002/14651858.CD010567.PUB2
Ann Hayes, Jackie Hunter, Why is publication of negative clinical trial data important British Journal of Pharmacology. ,vol. 167, pp. 1395- 1397 ,(2012) , 10.1111/J.1476-5381.2012.02215.X
Bassem Sadek, Ali Saad, Dhanasekaran Subramanian, Mohamed Shafiullah, Dorota Łażewska, Katarzyna Kieć-Kononowiczc, Anticonvulsant and procognitive properties of the non-imidazole histamine H3 receptor antagonist DL77 in male adult rats Neuropharmacology. ,vol. 106, pp. 46- 55 ,(2016) , 10.1016/J.NEUROPHARM.2015.10.023
Kinga Sałat, Adrian Podkowa, Szczepan Mogilski, Paula Zaręba, Katarzyna Kulig, Robert Sałat, Natalia Malikowska, Barbara Filipek, The effect of GABA transporter 1 (GAT1) inhibitor, tiagabine, on scopolamine-induced memory impairments in mice Pharmacological Reports. ,vol. 67, pp. 1155- 1162 ,(2015) , 10.1016/J.PHAREP.2015.04.018
Carla Ferrada, Estefanía Moreno, Vicent Casadó, Gerold Bongers, Antoni Cortés, Josefa Mallol, Enric I Canela, Rob Leurs, Sergi Ferré, Carme Lluís, Rafael Franco, Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. British Journal of Pharmacology. ,vol. 157, pp. 64- 75 ,(2009) , 10.1111/J.1476-5381.2009.00152.X
Dorota Łażewska, Katarzyna Kieć-Kononowicz, Recent advances in histamine H3 receptor antagonists/inverse agonists. Expert Opinion on Therapeutic Patents. ,vol. 20, pp. 1147- 1169 ,(2010) , 10.1517/13543776.2010.509346
Dorota Łażewska, Xavier Ligneau, Jean-Charles Schwartz, Walter Schunack, Holger Stark, Katarzyna Kieć-Kononowicz, Ether derivatives of 3-piperidinopropan-1-ol as non-imidazole histamine H3 receptor antagonists. Bioorganic & Medicinal Chemistry. ,vol. 14, pp. 3522- 3529 ,(2006) , 10.1016/J.BMC.2006.01.013
Dorota Łażewska, Małgorzata Więcek, Joanna Ner, Katarzyna Kamińska, Tim Kottke, J. Stephan Schwed, Małgorzata Zygmunt, Tadeusz Karcz, Agnieszka Olejarz, Kamil Kuder, Gniewomir Latacz, Marek Grosicki, Jacek Sapa, Janina Karolak-Wojciechowska, Holger Stark, Katarzyna Kieć-Kononowicz, Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands European Journal of Medicinal Chemistry. ,vol. 83, pp. 534- 546 ,(2014) , 10.1016/J.EJMECH.2014.06.032
Dorothée Kasteleijn- Nolst Trenité, Dominique Parain, Pierre Genton, Pascal Masnou, Jean-Charles Schwartz, Edouard Hirsch, Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: Dose-dependent effects in the human photosensitivity model Epilepsy & Behavior. ,vol. 28, pp. 66- 70 ,(2013) , 10.1016/J.YEBEH.2013.03.018